Neuroprotective Effects of Dalteparin on Experimental Traumatic Brain Injury in Rats

Hasan Çakir¹, Zeynep Nur Orhon²*, Cem Orhon³, E Nursen Koltka², Serdar Yeşiltaş¹ and Melek Çelik²

¹Department of Anesthesiology and Reanimation, Turkey
²Department of Anesthesiology and Reanimation, Medeniyet University, Turkey
³Department of Neurosurgery, Turkey
⁴Department of Anesthesiology and Reanimation, BezmiAlemVakif University, Turkey

Submission: June 07, 2018; Published: July 02, 2018

*Corresponding author: Zeynep Nur Orhon, Medeniyet University, Department of Anesthesiologyand Reanimation, Hizirbey CadCüre Apt. 221/4Göztepe, Istanbul, Turkey, Tel: 0 505 582 92 04; Email: zeynepnurorhon@gmail.com

Introduction

Brain injuries cause an immeasurable amount of human misery; lifelong physical, cognitive, or psychological impairment and pose a high cost burden to the community. Traumatic Brain Injury (TBI) is a common cause of mortality and morbidity among people less than 45 years of age throughout the World [1]. Acute damage in the brain occurs as a result of a mechanical trauma or subsequent interruption of the blood supply and leads a cascade of pathological events. TBI involves primary and secondary injury. Primary injury can be focal and/or diffuse and results from the mechanical forces and often leads to irreversible tissue damage. Secondary injury has different time courses, i.e., it may occur within minutes, hours, days or months following the primary insult and causes significant impairments of the brain functions and outcomes.

In TBI, edema and hemorrhage within and around the damaged tissue cause an increase in intracranial pressure that provokes compression of cerebral blood vessels, leading to reduced blood flow and ischemia [2]. Formation of microthrombi has been reported to occur in head trauma patients [3], and may contribute to the secondary ischemic insult. Autopsy results of more than 90% of the patients with fatal TBI showed the evidence of cerebral ischemia. According to these results, it was concluded that most of cerebral damage was secondary and occurred after an impact [4]. In some reports on autopsies in human and animal experiments, abundant fibrin microthrombi have been noted within cerebral vessels, particularly in and around cerebral contusions [3,5,6].

The development of treatment for brain trauma has focused on re-establishing blood flow to ischemic areas as quickly as possible,
mainly with antithrombotics or thrombolytics and on protecting neurons from cytotoxic events. This suggests that a therapeutic strategy with anticoagulant drugs is useful for treatment of brain injury. Anticoagulants such as heparin or Low Molecular Weight Heparin (LMWH) have been shown to be neuroprotective in focal cerebral ischemia in rats [7,8]. However, heparin possesses potent anticoagulant properties, acting on different coagulation factors like factor IIa (thrombin) or factor Xa (key component of the prothrombinase complex). Moreover, the main drawbacks of unfractionated heparin are the very short half-life and high risk of bleeding, which limits its use in clinical indications.

In contrast, LMWH has six times less anti-IIa activity and half anti-Xa activity compared with heparin, which reduces the risk of hemorrhage [9,10]. In addition to the anticoagulant effects, anti-inflammatory [7] and trophic properties [11] have been attributed to unfractionated heparin. Dalteparin is a LMWH with a mean molecular weight of 5,000 and it has anti-Xa activity. There are some reports about the effects of dalteparin in preventing thrombosis in deep arterial injury, on cellular apoptosis and inflammatory process in an incisional wound healing model and in induced liver injury [12-15]. However, in literature there is no report about the use of dalteparin in TBI. Therefore, in this study, we planned to investigate the therapeutic effect of dalteparin in experimental TBI in rats.

Material and Methods

Animals and Experimental Design

The present study was approved by Marmara University Animal Ethics Committee (Approval No: 87. 2013. mar). Thirty male Sprague-Dawley rats were enrolled in this experimental study. Ages of all rats were under 3 months. The average body weight was 250-300g. Animal care and all procedures were performed according to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication 85-23, revised 1985). Rats were maintained on a 12 h light–dark cycle and allowed free access to food and water. Temperature was kept at 20°C ± 2°C and humidity was 50% ± 10% at the animal facility. The animals were randomly divided into three groups (n=10 in each group). Group 1 (control group), Group 2 (trauma alone group), Group 3 (trauma+dalteparin treatment group).

Results

Biochemical Findings

Table 1: Malondialdehyde (MDA) (nm/mg protein), Superoxide Dismutase (SOD) (U/mg protein), Glutathione peroxidase (GPx) (U/mg protein), and Catalase (CAT) (k/mg protein) levels in all groups.

<table>
<thead>
<tr>
<th></th>
<th>Control Group</th>
<th>Trauma Group</th>
<th>Trauma+ Dalteparin Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA(nm/mg protein)</td>
<td>1.67±0.22</td>
<td>2.64±1.12*</td>
<td>2.04±0.25**</td>
</tr>
<tr>
<td>SOD (U/mg protein)</td>
<td>0.48±0.09</td>
<td>0.16±0.03*</td>
<td>0.27±0.04**</td>
</tr>
<tr>
<td>GPx (U/g protein)</td>
<td>30.55±0.79</td>
<td>16.5±2.57**</td>
<td>21.9±1.49**</td>
</tr>
<tr>
<td>CAT (k/mg protein)</td>
<td>0.41±0.01</td>
<td>0.19±0.09*</td>
<td>0.29±0.06**</td>
</tr>
</tbody>
</table>

MDA: Malondialdehyde; SOD: Superoxide dismutase; GPx: Glutathione peroxidase; CAT: Catalase

Kruskal-Wallis test was used for statistical analysis. All data were presented as the mean ± standard deviation. For each group, n=10. *P< 0.01 compared with the control group.

General anesthesia was administered through an intraperitoneal injection of ketamine (from Pfizer, Turkey) 90 mg/kg and xylazine 2% (Agrar Veterinary Pharmaceuticals, Netherlands) 10 mg/kg. The animals maintained spontaneous breathing. No trauma induction or treatment approach was implemented in the control group (Group 1). In trauma group (Group 2), severe trauma was induced using the weight dropping technique described by Shapira et al [16]. In the weight drop injury model, an anesthetized animal was placed under a ‘trauma device’ and was subjected to TBI using gravitational force of free-falling weight from 7 cm height onto the frontoparietal convexity (1-2 mm lateral to the midline) of the skull and an impact of 0.5 J was delivered to the intact skull. In trauma + treatment group (Group 3) severe trauma was induced as described for Group 2 and 15 minutes after the trauma 50IU/kg dalteparin (Fragmin; Pharmacia, Uppsala, Sweden, 25 000 IU/ml) was given intraperitoneally.

The dalteparin dose used for rats was comparable to that for human prophylaxis for the deep venous thrombosis after major surgical procedures. The animals were sacrificed 4h after the injury. Their brain tissues were removed and divided into two pieces. One of them was put in 10% formalin for histopathological analysis. The other one was immediately frozen in liquid nitrogen and stored at ~80°C until analyses. Analyses were performed mainly using 3 techniques; biological analysis, immunohistochemistry and light microscopy. Biological analysis were performed to detect the level of Malondialdehyde (MDA), Superoxide Dismutase (SOD), Glutathione Peroxidase (GPx) and Catalase (CAT). Immunohistochemistry was used to determine Caspase-3 activity whereas light microscopy was used to evaluate the histological appearance of the brain tissues of the rats.

Statistical Analysis

SPSS for Windows (version 11.0) was used for statistical analysis. All data were presented as the mean ± Standard Deviation (SD). The groups were compared by the Kruskal-Wallis test. A P-value of less than 0.05 was considered significant. When the P-value was less than 0.05, Mann-Whitney U Test was used for pair-wise comparisons between the groups.

The levels of MDA, SOD, GPx and CAT are shown in Table 1. Compared with control group, MDA level in the brain tissue increased significantly (P<0.01) and the amount of the antioxidant enzymes SOD, GPx ve CAT decreased significantly in trauma group (P<0.01). In trauma+dalteparin treatment group, MDA level was decreased significantly (P<0.05), and antioxidant enzyme levels (SOD, GPx and CAT) were increased significantly (P<0.05) (Figure 1).

Figure 1: MDA (nm/mg protein), SOD (U/mg protein), GPx (U/mg protein) and CAT (k/mg protein) levels in all groups. Kruskal-Wallis test was used for statistical analysis. All data were presented as the mean±Standard deviation (SD). For each group n=10. *P<0.01 compared to the control group; +P< 0.05 compared to the trauma group.

Light Microscopic Findings

Hematoxylin and eosin-stained slides containing frontal cortex of the control group showed normal ultrastructure of brain tissue and those containing frontal cortex of the trauma group showed severe degenerative changes in the neurons, puckered cytoplasm, dark stained picnotic nucleuses and vacualisation. In trauma+dalteparin group hematoxylin and eosin-stained slides containing frontal cortex showed decreased degenerative changes in neurons and a significant decrease in puckered cytoplasm, dark stained picnict nuclei and vacuolization (Figure 2).

Immunohistochemical Findings

Caspase-3 immunohistochemical evaluation of the neurons under the light microscope revealed that caspase-3 activity was insignificant in the control group, increased significantly in trauma group, and decreased significantly in trauma+dalteparin group (Figure 3). Table 2 shows the number of apoptotic neurons (caspase-3 immunopositive) in the groups. The amount of apoptotic neurons increased after the trauma and decreased with dalteparin treatment.

Discussion

Dalteparin treatment was found to be effective in improving all parameters evaluated in the study. Hematoxylin and eosin-stained slides containing frontal cortex of trauma group showed
severe degenerative changes in the neurons; puckered cytoplasm, dark stained picnotic nuclei, and vacuolization, i.e., edema formation in the tissue. In trauma + dalteparin group, hematoxylin and eosin-stained slides showed decreased degenerative changes in the neurons and a significant decrease in puckered cytoplasm, dark stained picnotic nuclei and vacuolization; MDA level was decreased significantly, antioxidant enzyme levels (SOD, GPx and CAT) were increased significantly, and caspase-3 activity was decreased significantly. This means that edema in the brain tissue, oxidative brain damage and degeneration in neurons were improved, the number of apoptotic neurons, was decreased by dalteparin treatment.

Table 2: The number of apoptotic neurons (caspase-3 immunopositive) in the groups (cell/µm²).

<table>
<thead>
<tr>
<th>Group</th>
<th>Frontal Cortex Tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>16.9 ± 1.3</td>
</tr>
<tr>
<td>Trauma</td>
<td>92.7 ± 9.4a</td>
</tr>
<tr>
<td>Trauma + Dalteparin</td>
<td>51.2 ± 5.1b</td>
</tr>
</tbody>
</table>

Kruskal-Wallis test was used for statistical analysis. All data were presented as the mean ± standard deviation. For each group, n=10.

As a result, they concluded that LMWH improved the pathological and behavioral effects of experimental TBI and enoxaparin or other LMWH could be used for the treatment of acute neurodegenerative diseases [19]. The preclinical data for enoxaparin in in vivo models of ischemia and brain trauma in rats were studied. In addition to anticoagulant effects, enoxaparin has many other pharmacological effects (i.e. reduction of intracellular Ca²⁺ release; antioxidant effect; anti-inflammatory or neurotrophic effects) that could act in synergy to explain the neuroprotective activity of enoxaparin in acute neurodegenerative diseases. Using the transient middle cerebral artery occlusion, demonstrated that in different in vivo models of acute neurodegenerative diseases, enoxaparin reduces brain edema and lesion size and improves motor and cognitive functional recovery with a largetherapeutic window of opportunity (compatible with a clinical application).

Taking into account these experimental data in models of ischemia and brain trauma, the clinical use of enoxaparin in acute neurodegenerative diseases warrants serious consideration [20]. The neuroprotective effects of AT III and enoxaparin were compared after severe traumatic brain injury. AT III has been more effective than enoxaparin in reducing neuronal cell death and it was concluded that AT III and enoxaparin could be used in the treatment of traumatic brain injuries [21]. According to our knowledge, dalteparin, an other LMWH, has not been used before in the treatment of experimental TBI. Thus, for this purpose, dalteparin was used for the first time by our group. The effect of dalteparin on the inflammation and cellular apoptosis was evaluated in an incisional wound-healing rat model, and it was concluded that dalteparin has an impact on suppressing early inflammatory process and leads to increase in cellular apoptosis, which impedes wound healing [12].

Based on this knowledge, we claimed that suppression of the early inflammatory process is one of the beneficial effects of dalteparin in TBI. Another study designed to examine the effects of dalteparin on ischemia/reperfusion injury found that dalteparin could improve liver injury in rats by reducing inflammatory responses. These therapeutic effects might play a critical role in preventing intravascular coagulation in TBI [14]. In several studies, it has been revealed that LMWHs are capable of inhibiting adhesion of human polymorphonuclear leukocytes to endothelial cells, the production of reactive oxygen species and the expression of cell adhesion molecules, L- and P-selectin, on endothelial cells [15,22-24]. We claim that the beneficial effect of dalteparin on improving the results after TBI is probably due to the mechanisms mentioned above.

In summary, we concluded that dalteparin given 15 minutes after TBI, improved brain edema, oxidative brain damage and...
Acknowledgements

The authors would like to acknowledge BAP Committee of Istanbul Medeniyet University for the financial support.

Ethical approval

All procedures were performed in accordance with the ethical standards of our institutional research committee and with those of the 1964 Helsinki declaration and its later amendments.

References
